GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a highly researched but unapproved substance frequently discussed in performance and anti-aging communities. The following information is strictly for educational and harm-reduction purposes.

What is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide consisting of six amino acids that mimics the hunger hormone ghrelin to stimulate the body's own release of growth hormone from the pituitary gland. Researched since 1984, it is not approved for medical therapy in Western markets.

Chemically known by its sequence (His-D-Trp-Ala-Trp-D-Phe-Lys) and the development code SKF-110679, this molecule belongs to the class of growth hormone secretagogues (GHS). While it is structurally related to Met-Enkephalin, it completely lacks any opioid-like activity. Instead, it functions as a deliberate activator of the ghrelin pathway. In human medicine, it has primarily been utilized as a diagnostic tool during GH stimulation tests, rather than as an approved therapeutic agent, due to a lack of long-term safety data.

How does GHRP-6 work?

GHRP-6 works by binding to the growth hormone secretagogue receptor 1a (GHS-R1a), mimicking ghrelin, which triggers a pulsatile release of growth hormone from the pituitary gland. It also binds to the CD36 receptor, providing protective effects to heart and liver cells, and strongly activates hypothalamic hunger regulators.

At the cellular level, this binding flips a series of molecular switches inside the cell that ultimately tell the pituitary to dump growth hormone into the bloodstream. Importantly, GHRP-6 has demonstrated selectivity in early research: at standard doses, it successfully stimulates GH without causing a parallel release of other pituitary hormones like LH, FSH, or TSH. However, it does reliably stimulate the release of ACTH, which subsequently raises cortisol levels.

Researchers have noted that GHRP-6 operates synergistically with Growth Hormone Releasing Hormone (GHRH). When both are present, GHRH initiates the pulse, while GHRP-6 significantly amplifies both the amplitude and duration of the growth hormone spike.

How effective is GHRP-6?

The clinical effectiveness of GHRP-6 for therapeutic applications is poorly documented, as the longest published human studies only tested single doses. While it reliably stimulates growth hormone release, proven long-term benefits for muscle building or recovery in humans are lacking, with most tissue-protective data coming from animal models.

In diagnostic human trials, GHRP-6 proved highly potent at triggering GH release. An intravenous dose of approximately 1 µg/kg reliably generated peak GH values between 15 and 50 µg/L in healthy subjects. Beyond growth hormone stimulation, preclinical models-particularly from Cuban research institutions-have shown that GHRP-6 exerts potent cytoprotective (cell-protecting) effects. These studies suggest it can protect heart tissue from chemotherapy-induced damage (such as from doxorubicin) and safeguard neuronal and liver tissues.

Dosage: what studies show - and the course

In clinical research, GHRP-6 has been administered via various routes including intravenously, orally, intranasally, and subcutaneously to test its growth hormone stimulating properties. Typical study protocols utilized single doses or short diagnostic bursts rather than long-term therapeutic courses, meaning no validated long-term dosing schedules exist for humans.

It is important to understand that the dosages frequently discussed in community forums are derived from historical study protocols and informal experimentation, not validated clinical guidelines. The substance has been tested in various formats, including oral capsules and sublingual delivery, though its effectiveness via non-injected routes in healthy individuals is not robustly proven.

Mixing & calculating dose

When prepared for subcutaneous injection in research settings, lyophilized GHRP-6 powder must be reconstituted with bacteriostatic water to create a measurable liquid solution. This process requires precise mathematical calculation to ensure accurate microgram dosing, as incorrect mixing can lead to severe dosing errors and unintended side effects.

For instance, if a vial contains 5 mg (5000 µg) of GHRP-6 powder, and it is reconstituted with 2.5 ml of bacteriostatic water, the resulting solution contains 2000 µg of the peptide per milliliter. On a standard insulin syringe (100 IU per 1 ml), 1 IU therefore corresponds to exactly 20 µg of GHRP-6. Because GHRP-6 acts on hormonal pathways that affect cortisol and blood sugar regulation, precise calculation is critical. Harm reduction dictates that reconstitution must be performed under sterile conditions, though it is vital to remember that unregulated black-market products entirely bypass pharmaceutical quality control.

Side effects and common mistakes

Documented side effects of GHRP-6 include a significantly increased appetite, water retention, and transient elevations of cortisol and prolactin levels. Because long-term human safety data is completely lacking, users risk unpredictable impacts on their cardiovascular system and blood sugar regulation when acquiring unregulated formulations from illicit sources.

In human trials, acute administration has been shown to safely activate the hypothalamic-pituitary-adrenal (HPA) axis without acute toxicity. However, the chronic, repeated stimulation of this stress axis (leading to sustained cortisol elevation) poses an unknown metabolic risk over time. Additionally, because GHRP-6 strongly mimics ghrelin, the resulting intense hunger can lead to substantial unwanted body fat accumulation if not strictly managed.

• Stacking blindly: Combining GHRP-6 with other peptides (like CJC-1295) amplifies hormonal effects without clinical safety data for long-term use.
• Assuming oral equivalence: Assuming that oral or sublingual administration matches the absorption and potency of subcutaneous injections without medical supervision.
• Ignoring cortisol: Overlooking the drug's tendency to raise cortisol and prolactin, which can lead to anxiety, water retention, and fatigue.
• Using unregulated products: Relying on black-market vials that lack pharmaceutical-grade sterility and accurate dosing labels.

Approval and legal status

GHRP-6 is not approved by the FDA or EMA for any therapeutic or cosmetic purpose and is listed as a prohibited substance by the World Anti-Doping Agency (WADA). In Germany, it is explicitly classified as a forbidden doping peptide, with possession of significant amounts being strictly regulated under federal law.

Specifically in Germany, GHRP-6 is named directly in the Federal Law Gazette (Bundesgesetzblatt Bgbl. I 2023 Nr. 67) under peptides that have effects similar to growth hormone-releasing factors. Under the German Doping Act (Dopinggesetz), possession of a "not minor amount" for performance enhancement is a criminal offense; for this specific peptide, that threshold is strictly defined as 150 mg. Across the USA and the broader EU, it is legally sold only as a research chemical and is illegal to market for human consumption.